• Users Online: 409
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2022  |  Volume : 5  |  Issue : 1  |  Page : 35-38

Role of axitinib and other tyrosine kinase inhibitors in the management of metastatic renal cell carcinoma


Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Nishtha Khatri
Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jco.jco_5_22

Rights and Permissions

The selection of chemotherapeutic agents in the management of metastatic renal cell carcinoma is a challenge as it has to strike a delicate balance between adverse effects and patient affordability based on the individual risk stratification. In this narrative review, authors have discussed about the various tyrosine kinase inhibitors available and the preference for axitinib as the first-line drug when used as a single agent or in combination with immunotherapeutic agents. This review article has been written based on a literature search of relevant articles conducted from September 2020 to December 2020 across PubMed and Google Scholar.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed66    
    Printed14    
    Emailed0    
    PDF Downloaded11    
    Comments [Add]    

Recommend this journal